Cover Image
市場調查報告書

OTC腸胃藥的全球市場 2015∼2019年

Global Gastrointestinal OTC Drugs Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 328830
出版日期 內容資訊 英文 101 Pages
訂單完成後即時交付
價格
Back to Top
OTC腸胃藥的全球市場 2015∼2019年 Global Gastrointestinal OTC Drugs Market 2015-2019
出版日期: 2015年04月15日 內容資訊: 英文 101 Pages
簡介

全球OTC腸胃藥市場,預計從2014到2019年以1.48%的年複合成長率(CAGR) 成長。

本報告提供全球OTC腸胃藥市場相關分析、市場概要和結構、市場規模趨勢 (今後5年的預測值)、醫藥品的各治療層級、適應症、地區的詳細趨勢、推動、阻礙市場要素與其影響力、主要企業簡介、今後的市場機會等調查、考察。

第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 概要:成藥

  • OTC認證的法規途徑
  • FDA的成藥認證流程
    • OTC NDA
    • 成藥專題文章
    • 腸胃處方藥的OTC轉換

第7章 腸胃疾病的流行病學

第8章 市場形勢

  • 市場概要
  • 市場規模、預測
  • 主要的預測
  • 波特的五力分析

第9章 市場區隔:各醫藥品的治療層級

  • 胃酸分泌抑制劑
  • 胃酸中和劑
  • 便秘藥
  • 腹瀉決定性的一擊藥
  • 制吐藥
  • 其他

第10章 市場區隔:各適應症

  • GRED (胃食道逆流症)
  • 便秘
  • 腹瀉
  • 暈車噁心
  • 腹脹

第11章 地區區分

  • 南北美洲的OTC腸胃藥市場
  • EMEA (歐洲、中東、非洲) 的OTC腸胃藥市場
  • APAC (亞太地區) 的OTC腸胃藥市場

第12章 購買標準

第13章 促進市場成長的要素

第14章 推動因素與其影響力

第15章 市場課題

第16章 推動因素、課題的影響力

第17章 市場趨勢

第18章 市場趨勢與其影響

第19章 業者情勢

  • 競爭情形
  • 市場佔有率分析
    • Bayer
    • GlaxoSmithKline
    • Johnson & Johnson
    • Perrigo
    • Pfizer
    • P&G
  • 其他有潛力的供應商

第20章 主要供應商分析

  • Bayer
  • GlaxoSmithKline
  • Johnson & Johnson
  • Perrigo
  • Pfizer
  • P&G

第21章 相關報告

圖表一覽

目錄
Product Code: IRTNTR5810

About gastrointestinal OTC drugs

OTC drugs are medications that do not require a prescription. In contrast, prescription drugs can be sold only to consumers having a legal prescription. OTC drugs are carefully chosen by regulatory agencies to ensure their safety and efficacy. Gastrointestinal OTC drugs can be bought off-the-shelf. Gastrointestinal OTC drugs are used for indications such as GERD, vomiting, constipation, diarrhea, and flatulence. Some of the OTC drugs that are available for the treatment of gastrointestinal diseases are laxatives, anti-flatulents, H2-antaginists, anti-diarrheals, PPIs, and anti-emetics. The OTC drugs are not bound by regulatory guidelines, but need to comply with the drug monograph of a country.

Technavio's analysts forecast the global gastrointestinal OTC drugs market to grow at a CAGR of 1.48% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global gastrointestinal OTC drugs market for the period 2015-2019. To calculate the market size, the report considers revenue from the sales of various OTC drugs available in the market for the management of gastrointestinal disorders such as:

  • GERD/Heartburn
  • Constipation
  • Diarrhea
  • Nausea due to motion sickness
  • Flatulence

The report presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. In addition, it discusses the major drivers that influence the growth of the market. It also discusses the challenges faced by the vendors and the market at large, as well as the key trends that contribute to the growth the market.

Technavio's report, Global Gastrointestinal OTC Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and EMEA and APAC; it also covers the global gastrointestinal OTC drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Bayer
  • GlaxoSmithKline
  • Johnson & Johnson
  • Perrigo
  • Pfizer
  • Procter & Gamble

Other Prominent Vendors

  • Abbott
  • Boehringer Ingelheim
  • C.B. Fleet
  • Nestle
  • Omega
  • Purdue Pharma
  • Reckitt Benckiser
  • Sanofi
  • Teva Pharmaceutical

Market driver

  • Increase in patient population
  • For a full, detailed list, view our report

Market challenge

  • High spending on advertisement
  • For a full, detailed list, view our report

Market trend

  • Strategic alliances
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market overview
  • 03.2. Product offerings

04. Market Research Methodology

  • 04.1. Market research process
  • 04.2. Research methodology

05. Introduction

06. Overview: OTC Drugs

  • 06.1. Regulatory pathways for OTC approval
  • 06.2. FDA OTC drug approval process
    • 06.2.1. OTC NDA
    • 06.2.2. OTC drug monograph
    • 06.2.3. Gastrointestinal prescription to OTC switch

07. Epidemiology of Gastrointestinal Disorders

08. Market Landscape

  • 08.1. Market overview
  • 08.2. Market size and forecast
  • 08.3. Top predictions
  • 08.4. Five forces analysis

09. Market Segmentation by Therapeutic Class of Drug

    • 09.1.1. Gastric acid reducers
    • 09.1.2. Gastric acid neutralizers
    • 09.1.3. Laxatives
    • 09.1.4. Antidiarrheals
    • 09.1.5. Antiemetics
    • 09.1.6. Others

10. Market Segmentation by Indication

    • 10.1.1. GERD
    • 10.1.2. Constipation
    • 10.1.3. Diarrhea
    • 10.1.4. Nausea caused by motion sickness
    • 10.1.5. Flatulence

11. Geographical Segmentation

  • 11.1. Gastrointestinal OTC drugs market in Americas
    • 11.1.1. Market size and forecast
  • 11.2. Gastrointestinal OTC drugs market in EMEA
    • 11.2.1. Market size and forecast
  • 11.3. Gastrointestinal OTC drugs market in APAC
    • 11.3.1. Market size and forecast

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

  • 19.1. Competitive scenario
    • 19.1.1. Key news
    • 19.1.2. Mergers and acquisitions
  • 19.2. Market share analysis 2014
    • 19.2.1. Bayer
    • 19.2.2. GlaxoSmithKline
    • 19.2.3. Johnson & Johnson
    • 19.2.4. Perrigo
    • 19.2.5. Pfizer
    • 19.2.6. P&G
  • 19.3. Other prominent vendors

20. Key Vendor Analysis

  • 20.1. Bayer
    • 20.1.1. Key facts
    • 20.1.2. Business overview
    • 20.1.3. Business segmentation by revenue 2014
    • 20.1.4. Business segmentation by revenue 2013 and 2014
    • 20.1.5. Geographical segmentation by revenue 2014
    • 20.1.6. Business strategy
    • 20.1.7. Recent developments
    • 20.1.8. SWOT analysis
  • 20.2. GlaxoSmithKline
    • 20.2.1. Key facts
    • 20.2.2. Business overview
    • 20.2.3. Business segmentation by revenue 2014
    • 20.2.4. Business segmentation by revenue 2013 and 2014
    • 20.2.5. Geographical segmentation by revenue 2014
    • 20.2.6. Business strategy
    • 20.2.7. Recent developments
    • 20.2.8. SWOT analysis
  • 20.3. Johnson & Johnson
    • 20.3.1. Key facts
    • 20.3.2. Business overview
    • 20.3.3. Business segmentation by revenue 2014
    • 20.3.4. Business segmentation by revenue 2013 and 2014
    • 20.3.5. Geographical segmentation by revenue 2014
    • 20.3.6. Business strategy
    • 20.3.7. Recent developments
    • 20.3.8. SWOT analysis
  • 20.4. Perrigo
    • 20.4.1. Key facts
    • 20.4.2. Business overview
    • 20.4.3. Business segmentation by revenue 2014
    • 20.4.4. Business segmentation by revenue 2013 and 2014
    • 20.4.5. Geographical segmentation by revenue 2014
    • 20.4.6. Business strategy
    • 20.4.7. Recent developments
    • 20.4.8. SWOT analysis
  • 20.5. Pfizer
    • 20.5.1. Key facts
    • 20.5.2. Business overview
    • 20.5.3. Business segmentation by revenue 2014
    • 20.5.4. Business segmentation by revenue 2013 and 2014
    • 20.5.5. Geographical segmentation by revenue 2014
    • 20.5.6. Business strategy
    • 20.5.7. Key developments
    • 20.5.8. SWOT analysis
  • 20.6. P&G
    • 20.6.1. Key facts
    • 20.6.2. Business overview
    • 20.6.3. Business segmentation by revenue 2014
    • 20.6.4. Business segmentation by revenue 2013 and 2014
    • 20.6.5. Geographical segmentation by revenue 2014
    • 20.6.6. Business strategy
    • 20.6.7. Recent developments
    • 20.6.8. SWOT analysis

21. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market research methodology
  • Exhibit 2: Comparison between prescription and OTC drugs
  • Exhibit 3: Advantages and disadvantages of OTC drugs
  • Exhibit 4: Ways to establish an OTC drug in different markets
  • Exhibit 5: Key regulatory bodies for OTC approval
  • Exhibit 6: FDA OTC drug approval process
  • Exhibit 7: Comparison of NDA versus OTC monograph process
  • Exhibit 8: Mechanisms to amend an OTC drug monograph
  • Exhibit 9: Drugs underwent Rx-to-OTC switch in US
  • Exhibit 10: Global gastrointestinal OTC drugs market 2014-2019 ($ million)
  • Exhibit 11: Top predictions in global gastrointestinal OTC drugs market
  • Exhibit 13: Global gastrointestinal OTC drugs market by therapeutic class of drug
  • Exhibit 14: Global gastrointestinal OTC drugs market by therapeutic class of drug 2014
  • Exhibit 15: Global gastrointestinal OTC drugs market by indication
  • Exhibit 16: Segmentation of global gastrointestinal OTC drugs market by geography 2014
  • Exhibit 17: Segmentation of global gastrointestinal OTC drugs market by geography 2019
  • Exhibit 18: Gastrointestinal OTC drugs market in Americas 2014-2019 ($ million)
  • Exhibit 19: Gastrointestinal OTC drugs market in EMEA 2014-2019 ($ million)
  • Exhibit 20: Gastrointestinal OTC drugs market in APAC 2014-2019 ($ million)
  • Exhibit 21: Key takeaways: Bayer
  • Exhibit 22: Key takeaways: GlaxoSmithKline
  • Exhibit 23: Key takeaways: Johnson & Johnson
  • Exhibit 24: Key takeaways: Perrigo
  • Exhibit 25: Product portfolio matrix of major vendors
  • Exhibit 26: Key takeaways: Pfizer
  • Exhibit 27: Key takeaways: P&G
  • Exhibit 28: Bayer: business segmentation by revenue 2014
  • Exhibit 29: Bayer: business segmentation by revenue 2013 and 2014 (US$ billion)
  • Exhibit 30: Bayer: geographical segmentation by revenue 2014
  • Exhibit 31: GlaxoSmithKline: business segmentation by revenue 2014
  • Exhibit 32: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billion)
  • Exhibit 33: GlaxoSmithKline: geographical segmentation by revenue 2014
  • Exhibit 34: Johnson & Johnson: business segmentation by revenue 2014
  • Exhibit 35: Johnson & Johnson: business segmentation by revenue 2013 and 2014 ($ billion)
  • Exhibit 36: Johnson & Johnson: geographical segmentation by revenue 2014
  • Exhibit 37: Perrigo: business segmentation by revenue 2014
  • Exhibit 38: Perrigo: business segmentation by revenue 2013 and 2014 ($ billion)
  • Exhibit 39: Perrigo: geographical segmentation by revenue 2014
  • Exhibit 40: Pfizer: business segmentation by revenue 2014
  • Exhibit 41: Pfizer: business segmentation by revenue 2013 and 2014 ($ billion)
  • Exhibit 42: Pfizer: geographical segmentation by revenue 2014
  • Exhibit 43: P&G: business segmentation by revenue 2014
  • Exhibit 44: P&G: business segmentation by revenue 2013 and 2014 ($ billion)
  • Exhibit 45: P&G: geographical segmentation by revenue 2014
Back to Top